Enjoy complimentary customisation on priority with our Enterprise License!
The global needle-free injection systems market size is estimated to grow by USD 15,375.4 million at a CAGR of 15.06% between 2022 and 2027.
The increasing preference for minimally invasive biopsies is driving the market growth. For screening and diagnosis of various types of cancer, like bone cancer, biopsies are used. The traditional biopsy procedure is still widely used; however, it is invasive and can cause complications like bruising, swelling, bleeding, and infections. To prevent these complications, needle-free injections have emerged as an alternative; they involve non-invasive procedures to detect certain molecular biomarkers for the early detection of diseases in patients. They also have the advantages of quick results and minimal risks involved. All these features are expected to have a positive impact on the demand for needle-free injection systems.
Technavio has segmented the market into End-User, Product, and Geography.
It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
The market share growth by the hospitals and clinics segment will be significant during the forecast period. Needle-free injection systems are mostly used in hospitals to administer vaccines, anticoagulants, biologics, and other pharmaceutical drugs and there is an increasing demand for needle-free injection drug delivery from healthcare professionals. This is due to ease of administration and accurate dosing.
Get a glance at the market contribution of various segments View a PDF Sample
The hospitals and clinics segment was valued at USD 5,004.27 million in 2017. Clinics and privately operated healthcare facilities that have highly skilled general medical practitioners offer diagnostic, therapeutic, or preventive healthcare treatment and care. The growth of this segment is due to the high number of hospital visits for treatment and the growing adoption of needle-free injection systems in hospitals and clinics, which are expected to propel the market growth during the forecast period.
The fillable segment, not pre-filled with drugs is witnessing market growth due to its increased ease of storage. Unlike the pre-filled needle-free injection systems, these systems have drugs filled from separate vials or ampoules. However, pre-filled needle-free injection systems are expected to witness demand growth due to the convenience and accurate dosage of administration. This is likely to result in a slight decline in the market growth of the fillable segment of the needle-free injection systems market during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 43% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period.
Within the region, the US is the largest market due to the widespread availability of insurance coverage and reimbursements and increasing R and D expenditure. The demand for self-administered drugs, increasing awareness about safe injectable technology, and high healthcare spending are also factors that are increasing the demand for the needle-free injection systems market in the US. Additional safety features and the presence of advanced medical facilities drive market growth, especially in states such as Indiana, Ohio, and Illinois. Besides the US, Canada is also a major revenue contributor due to the rapid adoption of advanced needle-free devices. Hence the above factors are likely to contribute to the growth of the regional market during the forecast period.
The outbreak of COVID-19 positively impacted the regional needle-free injection systems market. Due to the rise in COVID-19 patients and the large-scale government-driven vaccination drives in Q4 2020, the demand for hypodermic needles increased in 2020. This also resulted in the growth of the needle-free injection systems market. Additionally, after the easing of restrictions, clinics and hospitals returned to the resumption of operations in the first half of 2021. Due to the greater number of patients seeking treatment and checkups in the region, the growth of the regional needle-free injection systems market is likely to grow further during the forecast period.
Buy Now Full Report and Discover More
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market vendors, including:
Antares Pharma Inc. - The company offers needle-free injection systems such as VIBEX and QuickShot.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The increasing preference for minimally invasive biopsies is driving market growth. Biopsies are widely used for the early-stage detection of cancers and to help in diagnosis through procedures like fine-needle aspiration cytology (FNAC) biopsy, core needle biopsy, image-guided biopsy, and surgical biopsy procedures. Despite the vast usage and simplicity of traditional bone and other biopsy procedures, the prevalence of side effects has increased the demand for needle-free injection biopsies. A needle-free biopsy is a non-invasive procedure and is used to detect certain molecular biomarkers.
Additionally, the non-invasive nature, enhanced assessment of tumor heterogeneity, and the increasing possibility of performing regular follow-up examinations are among several advantages which shall result in the increasing adoption of needle-free biopsy testing for disease detection. Hence, due to the above factors, the growth of the needle-free injection systems market is likely to grow during the forecast period.
The increasing incidence of needlestick infections is a key trend in the market. Needles are widely used in hospitals and clinics for the diagnosis, prevention, and treatment of infectious diseases. However, unsafe injection practices can leave patients vulnerable to infectious diseases. Usage of reused or contaminated needles and other unsafe injection practices have increased patient exposure and resulted in the contraction of infectious diseases, such as hepatitis B, hepatitis C, and human immunodeficiency virus (HIV).
Additionally, side effects like swelling, pain, rash, redness, or bleeding at the site of injection are common results of poor healthcare practices. Therefore, the safe usage of injectable medications by proper sterilization of needles for preventing infectious disease transmission is vital. Hence, the health risks associated with needle-administered injections shall provide opportunities for the global needle-free injection systems market to grow during the forecast period.
Stringent regulations on medical devices are challenging market growth. This is greatly due to reported periodic recalls of products and regulatory issues over the years. Classification of medical devices as per the US FDA ranges from Class I (for relatively low-risk products) to Class III (that are subject to the highest level of scrutiny). Hence, needle-free injection systems must undergo standard clinical trials, which are time-consuming, expensive, and uncertain.
Additionally, failure at any single stage of the clinical trial can result in rejection. Furthermore, rules and regulations about approval processes regarding medical devices vary from country to country, and regulatory policies by government agencies, including the US FDA, are subject to frequent revision. In the case of product development during such revision of regulatory policies, it can pose a serious challenge to launching it in the market. Hence government and regulatory bodies formed regulations that can pose a restriction on the market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Needle-Free Injection Systems Market Customer Landscape
The needle-free injection systems market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Needle-Free Injection Systems Market Scope |
|
Report Coverage |
Details |
Page number |
145 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 15.06% |
Market growth 2023-2027 |
USD 15,375.4 million |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
13.29 |
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
Performing market contribution |
North America at 43% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aijex Pharma International Inc., AKRA DERMOJET, Amico Group, Antares Pharma Inc., Becton Dickinson and Co., Endo International Plc, Ferring BV, Inovio Pharmaceuticals Inc., Lepu Medical Technology Beijing Co. Ltd., Medbitz Pte Ltd., Mika Medical Co., NuGen Medical Devices, QUINOVARE and TECHiJET, Technologies Médicales Internationales Inc., West Pharmaceutical Services Inc., Crossject, Needle Free Injection System, PharmaJet Inc., PORTAL INSTRUMENTS INC, and Recipharm AB |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.